Sign up online today & collaborate
or click here to find out more
A pioneering cancer drug that harnesses the power of the immune system has been approved for use in the UK.
Nivolumab was one of the drugs labelled a "milestone" therapy at a major cancer conference last month.
It has now been approved through the UK's Early Access to Medicines Scheme, which fast-tracks promising new therapies.
The drug has been shown to stop skin and lung cancers from progressing, in clinical trials.
The immune system is a powerful defence against infection. However, there are many "brakes" built in to stop the system attacking its own tissues.
Cancer - which is a corrupted version of healthy tissue - can take advantage of these brakes to evade assault from the immune system.
Nivolumab takes the brakes off.For more click here